Get a reality check on the organ-on-a-chip market

Organ chips are getting real backing from industry, regulators and even NASA.

We've found a lot of interesting signals. For example, in April 2026, Emulate's bone marrow chips, made from the Artemis II astronauts' own cells, flew around the Moon to study how deep space affects human cells. In August, Bruker announced a majority investment in MIMETAS, a Dutch organ chip maker. And in September, the FDA issued a rule that swaps "animal" for "nonclinical" in its drug safety regulations, wording that leaves room for methods like organ chips. Chips are being flown, bought and written into the rules.

In this section, we look at why drug makers want human-based tests now, which buyers are paying for them today, and what deals like this one mean for the independent chip makers.

A drug can look safe in animals and still harm people. Drug makers want tests that act more like a human organ, but they won't drop a method they trust until a new one has proved itself.

We compare six kinds of organ-chip companies, from single-organ and multi-organ systems to patient-derived chips, instruments, testing services and AI-driven platforms. Their buyers range from big pharma safety teams to biotech startups, contract labs and academic centers. Then we rank what hurts most: chips that run too few tests at once, results regulators have not yet accepted, and the work of learning a new system.

This shows which problems drug makers will pay to solve now, and which ones they still handle with animal studies and older methods.

Instrument sales, single-use chips and plates, testing services, data deals and pharma partnerships: organ-chip companies earn money in many ways.

We break down who pays for each model and what serving that customer costs. An instrument brings one big sale, then repeat orders for the chips used on it, but labs must first be convinced to buy. Running tests as a service wins pharma budgets faster, but it needs lab staff, so margins are thinner and growth depends on hiring. Selling data or models only works once enough studies have made them trusted. And many drug maker contracts start as small pilots.

You'll see which models can grow without adding a lab for every new customer, and which ones depend on a few big drug makers to keep paying.

Growth numbers alone say little. So we look at what makes drug makers move real budgets to organ chips.

The obvious drivers are rules that open the door to non-animal tests, public money for human-based methods, and the wish to catch toxic drugs before human trials. Others feed each other. Every study that matches human results makes the next one easier to trust. Faster chips bring down the price of each test. And once one drug maker uses a chip model in a filing, others are more willing to follow.

Before building or investing, you should know what moves a drug team from a pilot on a few chips to using them for real decisions, and what keeps it ordering once the pilot ends.

Emulate and CN Bio come up first when people talk about organ chips, but they are only part of the market.

Many interesting players work quietly. Some build nerve chips to test whether a drug damages nerves. Others focus on the kidney, or link several organs so a drug's effect on the liver and gut shows up at once. Some make chips from a patient's own cells. Others build the pumps, plates and imaging tools that chips run on.

They're hard to tell apart because almost every company says its chip is the most human-like, and there is no single test that proves it. Many also sell tests as a service to a few drug makers who don't name them, so real traction is rarely public.

Below, you'll find the market grids and ecosystem maps we've built to show who makes chips, who runs tests and who supplies the tools, and where newer players fit.

Vivodyne, Hesperos, Quris-AI… a few organ-chip companies have found drug makers willing to use their results. Their models differ, and each still has something to prove.

Vivodyne runs drug tests on lab-grown human tissues with robots and AI, and says most large drug companies use its technology, though it names no customers. Hesperos built a human-on-a-chip nerve model whose data Sanofi used to support a clinical trial application. Quris-AI combines AI with chip systems, and Merck KGaA says it built the platform into its safety testing. Each found a way in, but none has shown that one approach works for every drug or buyer.

We'll look at how these teams picked one job drug makers needed done, produced data a regulator could use, and kept customers after the first pilot.